Omnicell

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Santa Clara, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Omnicell reports robust Q4 earnings, eyes Advanced Services growth

Omnicell's Q4 2022 earnings call highlighted a strong financial performance, cost-saving initiatives, and strategic priorities for 2023. The company aims to drive growth through Advanced Services expansion, while navigating challenges such as market conditions and regulatory impacts. By focusing on operational efficiency and prudent financial management, Omnicell positions itself for sustainable growth and profitability.

Omnicell surpasses Q1 revenue targets, eyes automation for growth

Omnicell's Q1 2023 earnings call showcased robust financial performance, strategic partnerships, and cost containment efforts. The company is well-positioned to capitalize on the growing demand for automation in healthcare.

Omnicell surpasses Q2 expectations, focuses on AI strategy growth

Omnicell's Q2 performance exceeded expectations, driven by strong revenues and margins.
The company's strategic strengths lie in customer wins, AI focus, and margin management.
Challenges include market dynamics and the need for ongoing adjustments.
Opportunities for growth include raised guidance, AI strategy development, and CMS impact.

Omnicell reports Q3 earnings, faces challenges but eyes growth opportunities

Omnicell's Q3 2023 performance reflects solid total revenues, EBITDA, and EPS, with market challenges impacting bookings and product lines. The company's strengths include customer wins, profitability, and strategic growth initiatives.
Challenges include revenue impact from reduced bookings, point-of-care revenue decline, and pipeline deal deferrals. Opportunities exist in Advanced Services growth, market expansion, and cost management strategies.
Omnicell's focus on profitability, revenue growth, and customer value delivery positions it for future success. The company's strategic actions and financial outlook indicate a proactive approach to addressing challenges and seizing opportunities.

Omnicell reports Q4 revenue decline but sees growth opportunities ahead

Omnicell's Q4 2023 performance saw revenue decline but highlighted strategic wins and a focus on operational optimization.
The company's strengths lie in customer engagement, product upgrades, and expansion into new markets.
Challenges include industry costs and regulatory hurdles, but opportunities exist in market growth and service enhancements.
Overall, Omnicell remains optimistic about future demand and revenue potential, with a conservative outlook for Q1.

Omnicell surpasses Q1 revenue targets, exits product line for value

Omnicell's Q1 2024 earnings call showcased strong performance exceeding guidance, with a focus on cost management and strategic initiatives. The company announced plans to exit an international product line to improve shareholder value. Opportunities lie in the growth of the XT Amplify program and EnlivenHealth brand, despite challenges in revenue decline and operational decisions.

Omnicell reports robust Q3 earnings, eyes growth in healthcare solutions

Omnicell's Q3 2024 performance reflects strong revenue growth and operational resilience in healthcare solutions.
The company's strategic focus on customer-centricity and innovation positions it for sustained success.
Challenges in product revenue timing and cost optimization require ongoing attention for operational efficiency.
Opportunities in expanding services and market positioning offer avenues for future growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Fort Worth, TX.

Amedisys

Chemed

MDU Resources Group

Oasis Midstream Partners

Companies displaying high earnings growth along with high leverage ratios should be avoided while making investment decisions. So, investors should select companies with low leverage.

Invest in These 5 Low Leverage Stocks Before Q4 Earnings

Johnson & Johnson

Gibraltar Industries

Debt level of a company is an important point of consideration while making an investment decision.

Bet on These 5 Low Leverage Stocks to Invest Judiciously

Investor confidence in Omnicell (OMCL) is at a high, thanks to solid prospects.

Here's Why You Should Add Omnicell to Your Portfolio Now

Omnicell (OMCL) partners Huron to provide customers with committed expertise.

Omnicell-Huron Sign a Pact for Outcome-Based Expert Services

PC Connection

Lululemon Athletica

WellCare Health Plans

Debt is a much cheaper form of financing than equity. Yet the fact that debt carries the burden of interest payments makes it dearer.

Worried About Market Downturn? Buy These Low Leverage Stocks

This partnership will offer Omnicell (OMCL) the state-of-the art technology and medication intelligence needed to ensure accurate delivery of drugs to the right patients.

Omnicell (OMCL) Partners With Kit Check to Offer Bluesight

Omnicell (OMCL) to showcase innovations in medication management solution portfolio to minimize human errors by care providers.

Omnicell to Feature Upgrades in Medication Management at ASHP

Omnicell's (OMCL) diligent focus on product innovation through R&D is encouraging.

Omnicell (OMCL) Rides on Global Expansion, Strategic R&Ds

CECO Environmental Corp

Manulife Financial

SolarEdge Technologies

To safeguard one's portfolio from massive losses, the real challenge for an investor is to determine whether an organization's debt level is sustainable.

Buy These 5 Low Leverage Stocks to Keep Your Portfolio Safe

Syneos Health

SYNH vs. OMCL: Which Stock Is the Better Value Option?

SYNH vs. OMCL: Which Stock Should Value Investors Buy Now?

Omnicell (OMCL) continues to see solid segmental contributions in Q3. Expansion of gross and operating margins is a positive too.

Omnicell (OMCL) Beats on Q3 Earnings, Raises '19 EPS View

Omnicell, Inc. (OMCL) CEO Randall Lipps on Q3 2019 Results - Earnings Call Transcript

Omnicell (OMCL) delivered earnings and revenue surprises of 5.56% and -1.60%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Omnicell (OMCL) Q3 Earnings Surpass Estimates

Considering the weak penetration level in the international market, which is even less than 1%, Omnicell (OMCL) is rapidly exploring the uncharted overseas markets.

Omnicell Advances on Global Footing Despite Severe Rivalry

Omnicell (OMCL) aims to combine technology and innovation to enable pharmacists to expand their outreach to patients and improve services.

Omnicell's Autonomous Pharmacy to Boost Medication Management

Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock?

Omnicell (OMCL) Up 0.4% Since Last Earnings Report: Can It Continue?

Investor confidence continues to be high on Omnicell's (OMCL) prospects.

Here's Why You Should Hold Onto Omnicell (OMCL) Stock for Now

Omnicell (OMCL) aims at product innovation through R&D.

Omnicell (OMCL) Beats on Earnings in Q2, Tapers '19 EPS View

Omnicell, Inc. (OMCL) CEO Randall Lipps on Q2 2019 Results - Earnings Call Transcript

Omnicell (OMCL) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Omnicell (OMCL) Catches Eye: Stock Jumps 8.2%

Shares of Omnicell rebounded Monday after the automated pharmacy company refuted claims from short-seller GlassHouse Research that it had prematurely recognized $38.3 million in revenue.
The post Medical Stock Refutes Damning Short-Seller Report — And Bounds Higher appeared first on Investor's Business Daily.

Medical Stock Refutes Damning Short-Seller Report — And Bounds Higher

Cadiz

GameStop

Despite the Dow hitting 27,000 for the first time, not every stock participated in the rally.

Why GameStop, Omnicell, and Cadiz Slumped Today

Omnicell tumbled Thursday after a short-seller accused the automated pharmacy company of "accounting gimmicks," including prematurely recording revenue and not writing off legacy inventory.

This Medical Stock Has Popped 78%; A Short-Seller Calls It A Scam

Omnicell (OMCL) is boosting investors' optimism, courtesy of consistent positive results.

News for Omnicell Stock (OMCL)